1. A method for obtaining ex vivo enriched regulatory CD4 + CD25 + Foxp3 + T-cells (Treg) a population of human lymphocytes comprising a selection from the peripheral blood of the patient population CD4 + T cells and culturing them in a growth medium comprising a mixture of cytokines and antibodies consisting of 10-1000 units / ml interleukin-2 (IL-2), 0.5-10 ug / ml of monoclonal antibodies against human CD3-antigen (anti-CD3), 0.1-10 ug / ml of monoclonal antibodies against CD28- human antigen (anti-CD28), and 1-50 ng / ml transforming growth factor-β1 (TGF-β1), wherein said population of T-l mfotsitov contains at least 70% of regulatory T-cells. ! 2. A method of treating a disease characterized by a pronounced decrease in the number and / or functional activity of regulatory T cells comprising administering to a patient in rich regulatory T cells (Treg) lymphocytes autologous population obtained according to the method of claim 1. ! 3. The method of claim 2, wherein said disease is an autoimmune disease. ! 4. The method of claim 2, wherein said disease is an allergic disease. ! 5. The method of claim 2, wherein said disease is graft rejection. ! 6. The method of claim 2, wherein said disease is a reaction "graft versus host".
展开▼
机译：1.一种获得人淋巴细胞群的离体富集的调节性CD4 + CD25 + Foxp3 + T细胞（Treg）的方法，所述细胞包括从患者群CD4 + T细胞的外周血中选择的，并在包含以下成分的生长培养基中培养它们：细胞因子和抗体的混合物，由10-1000单位/毫升的白介素2（IL-2），0.5-10 ug / ml的针对人CD3抗原的单克隆抗体（抗CD3），0.1-10 ug / ml的抗CD28-人类抗原的单克隆抗体（抗CD28）和1-50 ng / ml转化生长因子-β1（TGF-β1），其中所说的T1 mfotsitov群体含有至少70％的调节性T细胞。 ！ 2.一种治疗以调节性T细胞的数目和/或功能活性显着降低为特征的疾病的方法，其包括向患者施用根据权利要求1的方法获得的丰富的调节性T细胞（Treg）淋巴细胞自体群体。 ！ 3.权利要求2的方法，其中所述疾病是自身免疫疾病。 ！ 4.权利要求2的方法，其中所述疾病是过敏性疾病。 ！ 5.权利要求2的方法，其中所述疾病是移植排斥。 ！ 6.权利要求2的方法，其中所述疾病是“移植物抗宿主”反应。
展开▼
